Stockhub

Gene Biotherapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 August 2022

12 August 2022

7 August 2022

  • curprev 12:5412:54, 7 August 2022 >Paris 998 bytes +998 Created page with "Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease...."
Retrieved from "https://stockhub.co/research/Gene_Biotherapeutics,_Inc."